The study evaluates Myobloc's efficacy in treating sialorrhea in ALS patients, a condition with limited treatment options. If successful, this could position Myobloc as a preferred therapy in a niche market, potentially expanding its use beyond existing indications. The ALS market is characterized by high unmet needs, and successful outcomes could lead to increased adoption and market share. Competitive landscape includes other botulinum toxin products and anticholinergic medications, but Myobloc's unique mechanism may offer advantages in refractory cases. Diligence should focus on the safety profile and long-term effects, as well as potential regulatory hurdles for expanded indications.